Stella Pharma Corporation Share Price

Equities

4888

JP3399680002

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 26/04/2024 am IST 5-day change 1st Jan Change
292 JPY +0.69% Intraday chart for Stella Pharma Corporation +10.19% +2.46%

Financials

Sales 2022 100 15.61K 8.34K Sales 2023 229 35.74K 19.11K Capitalization 11.49B 1,792B 958B
Net income 2022 -767M -120B -64B Net income 2023 -778M -121B -64.92B EV / Sales 2022 15,25,84,976 x
Net cash position 2022 2.02B 316B 169B Net cash position 2023 1.62B 252B 135B EV / Sales 2023 4,30,92,444 x
P/E ratio 2022
-22.1 x
P/E ratio 2023
-14.4 x
Employees 46
Yield 2022 *
-
Yield 2023
-
Free-Float 50.76%
More Fundamentals * Assessed data
Dynamic Chart
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 CI
Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023 CI
Stella Pharma Corporation announced that it has received funding from SMBC Nikko Securities Inc. CI
Stella Pharma Corporation announced that it expects to receive funding from SMBC Nikko Securities Inc. CI
Stella Pharma Corporation Provides Earnings Guidance for the Year Ending March 31, 2023 CI
Mizuho Securities Co., Ltd. acquired unknown minority stake in Stella Pharma Corporation from INCJ, Ltd. CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 18-OCT-2021. CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 20-JUL-2021. CI
Stella Pharma Corporation has completed an IPO in the amount of ¥3.400044 billion. CI
Stella Pharma Corporation has filed an IPO in the amount of ¥3.769614 billion. CI
Stella Pharma Corporation announced that it has received ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan CI
Stella Pharma Corporation announced that it expects to receive ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan CI
More news
1 day+0.69%
1 week+10.19%
Current month+0.34%
1 month+1.74%
3 months+9.77%
6 months+5.42%
Current year+2.46%
More quotes
1 week
275.00
Extreme 275
298.00
1 month
260.00
Extreme 260
311.00
Current year
229.00
Extreme 229
320.00
1 year
229.00
Extreme 229
366.00
3 years
229.00
Extreme 229
1 070.00
5 years
229.00
Extreme 229
1 070.00
10 years
229.00
Extreme 229
1 070.00
More quotes
Managers TitleAgeSince
Chairman 53 01/07/01
President 46 01/07/01
Director/Board Member - -
Members of the board TitleAgeSince
Director/Board Member 65 01/15/01
Director/Board Member 69 01/17/01
Director/Board Member 49 01/16/01
More insiders
Date Price Change Volume
26/24/26 292 +0.69% 43,700
25/24/25 290 -1.36% 71,200
24/24/24 294 +5.00% 84,200
23/24/23 280 +1.08% 41,900
22/24/22 277 +4.53% 93,600

Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST

More quotes
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
Calendar
More about the company